Every Form 4 that Clene Inc. (CLNN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CLNN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CLNN filings page.
Clene Inc. (CLNN) director David J. Matlin acquired additional common stock. On September 16, 2026, he purchased 434,451 shares of Clene common stock at $3.28 per share in a registered direct offering directly from the company, an issuance approved by the board under Rule 16(b)-3.
Following this transaction, Matlin holds 912,275 shares directly and 7,500 shares indirectly through the Matlin Family Trust 2020, which he serves as trustee and may beneficially own. No Rule 10b5-1 trading plan is reported for these purchases.
Clene Inc. (CLNN) reported that President & CEO and director Robert Dee Etherington acquired common stock. On September 16, 2026, he purchased 15,244 shares of common stock at $3.28 per share in a registered direct offering approved by the board under Rule 16(b)-3, bringing his directly held position to 55,393 shares. He also reports indirect holdings through an LLC and a revocable trust.
Clene Inc. (CLNN) reported that director and ten percent owner Alison Mosca had 198,171 shares of common stock acquired on September 16, 2026, by Kensington Clene 2021, LLC at $3.28 per share in a registered direct offering approved under Rule 16(b)-3. After this grant, Kensington Clene 2021, LLC holds 478,671 shares indirectly associated with Ms. Mosca, who is the sole manager and a minority owner and disclaims any interest beyond her pecuniary stake. Separate from this LLC position, Ms. Mosca reports 1,973 shares held directly, 150,333 shares held indirectly through Kensington Investments, L.P., and 72,997 shares held indirectly through the Robert C. Gay 1998 Family Trust, with the filing stating she has no pecuniary interest in the trust-held shares and disclaims interests where she lacks a profits interest. No transactions were reported under a Rule 10b5-1 trading plan.
Clene Inc. reported that director Matthew Kiernan received a grant of 3,195 stock options for common stock under the Clene Inc. Amended 2020 Stock Plan. The options have an exercise price of $4.19 per share, vest immediately upon grant, and expire on August 12, 2036. Following this grant, Kiernan holds 3,195 derivative securities representing the right to acquire an equal number of common shares.
Clene Inc. director Arjun JJ Desai received a grant of 3,674 stock options on August 13, 2026 under the Clene Inc. Amended 2020 Stock Plan. Each option has an exercise price of $4.19 per share and is exercisable for common stock. According to the grant terms, the options vest immediately upon grant and expire on August 12, 2036, resulting in post-transaction direct holdings of 3,674 options.
Clene Inc. reported that director Alison Mosca received a grant of 4,872 stock options on August 13, 2026 under the Clene Inc. Amended 2020 Stock Plan. The options have an exercise price of $4.19 per share, vest immediately upon grant, and expire on August 12, 2036, leaving her with 4,872 derivative securities outstanding from this grant.
Clene Inc. director David J. Matlin received a grant of 6,230 stock options on August 13, 2026 under the Clene Inc. Amended 2020 Stock Plan. The options have an exercise price of $4.19 per share, vest immediately upon grant, and are exercisable into 6,230 shares of common stock until August 12, 2036. Following this award, Matlin holds 6,230 stock options directly.
Clene Inc. director Shalom Jacobovitz received a grant of stock options for 4,752 shares of common stock on August 13, 2026 under the Clene Inc. Amended 2020 Stock Plan. The options have an exercise price of $4.19 per share, vest immediately upon grant, and expire on August 12, 2036. Following this award, Jacobovitz holds 4,752 stock options directly.
Clene Inc. director Jonathon Gay received a compensatory grant of 3,794 stock options on August 13, 2026 under the Clene Inc. Amended 2020 Stock Plan. The options have an exercise price of $4.19 per share, vest immediately upon grant, and are exercisable into 3,794 shares of common stock until August 12, 2036. Following this award, Gay holds 3,794 derivative securities directly.
Clene Inc. director Vallerie McLaughlin received a stock option grant for 3,514 shares of common stock on August 13, 2026 under the Clene Inc. Amended 2020 Stock Plan. The option has an exercise price of $4.19 per share, vests immediately upon grant, and expires on August 12, 2036. Following this grant, she holds options for 3,514 shares directly.
Clene Inc. director Reed N. Wilcox reported a grant of stock options for 3,514 shares of common stock on August 13, 2026 under the Clene Inc. Amended 2020 Stock Plan. The options have an exercise price of $4.19 per share, vest immediately upon grant, and expire on August 12, 2036. Following this award, Wilcox holds 3,514 options directly.
Clene Inc. insider Chidozie Ugwumba reported an internal restructuring on July 17, 2026, disposing of beneficial ownership of warrants over 799,358 Clene common shares that had been held indirectly through SymBiosis II LLC. Management of the fund’s portfolio shifted to an unaffiliated manager; no warrants were exercised, sold, transferred, or paid for, and Ugwumba ceased to be a ten percent owner subject to Section 16.
Clene Inc. reported that Chief Science Officer Mark Mortenson received a grant of stock options covering 45,000 shares of common stock. The options have an exercise price of $5.53 per share and expire on June 10, 2036. According to the grant terms, 25% of the options vest on June 11, 2027, with the remaining shares vesting in 36 equal monthly installments starting July 11, 2027. This is a compensation-related award, not an open-market stock purchase or sale.
Clene Inc. reported that President and CEO Robert Dee Etherington received a grant of stock options covering 65,000 shares of common stock. The options have an exercise price of $5.53 per share and expire on June 10, 2036. According to the grant terms, 25% of the options vest on June 11, 2027, with the remaining shares vesting in 36 equal monthly installments starting on July 11, 2027 until fully vested. This is a compensation-related award rather than an open-market purchase or sale.
Clene Inc. reported that Chief Financial Officer Morgan R. Brown received a grant of stock options covering 15,000 shares of common stock. The options have an exercise price of $5.53 per share and expire on June 10, 2036. They vest 25% on June 11, 2027, with the remaining shares vesting in 36 equal monthly installments beginning July 11, 2027. This is a compensation-related award rather than an open‑market share purchase or sale.
Clene Inc. director Vallerie McLaughlin received stock option awards as equity compensation. On May 21, 2026, she was granted options covering a total of 3,564 shares of common stock at an exercise price of $6.81 per share under the Clene Inc. Amended 2020 Stock Plan.
One option grant for 2,064 shares vests immediately, giving her the right to purchase those shares at the set price. A second option grant for 1,500 shares vests in 12 equal monthly installments on the 21st of each month starting June 21, 2026, extending through the following year. Both option series expire on May 20, 2036 if not exercised.
Clene Inc. director Arjun JJ Desai received new stock option awards. On May 21, 2026, he was granted options for 2,158 and 1,500 shares of common stock at an exercise price of $6.81 per share under the Amended 2020 Stock Plan. The 2,158-share option vests immediately, while the 1,500-share option vests in 12 equal monthly installments starting on June 21, 2026. These are compensation-related grants with no open-market purchases or sales reported.
Clene Inc. director Alison Mosca reported receiving two grants of stock options as part of her compensation. One grant covers 2,861 options for common stock at an exercise price of $6.81 per share and vests immediately. A second grant covers 1,500 options at the same $6.81 exercise price and vests in 12 equal monthly installments on the 21st of each month beginning June 21, 2026. Both option awards expire on May 20, 2036, and represent equity-based awards rather than open-market share purchases or sales.
Clene Inc. director David J. Matlin reported receiving two stock option awards on May 21, 2026, totaling 5,159 options for common stock at an exercise price of $6.81 per share. One grant for 3,659 options vests immediately, while a 1,500-option grant vests in 12 equal monthly installments beginning on June 21, 2026. Both option awards expire on May 20, 2036 and represent equity compensation, with no open-market share purchases or sales reported.
Clene Inc. director Shalom Jacobovitz received two stock option awards as equity compensation. One option covers 2,791 shares of common stock at an exercise price of $6.81 per share and vests immediately. The second option covers 1,500 shares at the same exercise price and vests in 12 equal monthly installments starting on June 21, 2026.
These awards are structured as derivative securities that can be exercised into common stock before their expiration on May 20, 2036, and reflect routine compensation rather than open-market buying or selling.
Clene Inc. director Matthew Kiernan reported receiving two stock option awards as equity compensation. He was granted options on 1,876 and 1,500 shares of common stock, each with an exercise price of $6.81 per share, expiring on May 20, 2036.
The 1,876-share option vests immediately, while the 1,500-share option vests in 12 equal monthly installments starting on June 21, 2026. These are grants/awards, not open‑market purchases or sales.
Clene Inc. director Jonathon Gay reported receiving two stock option awards. One option covers 2,228 shares of common stock at an exercise price of $6.81 per share and vests immediately. A second option covers 1,500 shares at the same exercise price and vests in 12 equal monthly installments starting on June 21, 2026, with both options expiring on May 20, 2036.
Clene Inc. director Reed N. Wilcox received two stock option grants as equity compensation. On May 21, 2026, he was awarded options for 2,064 shares of common stock at an exercise price of $6.81 per share that vest immediately.
On the same date, he was also granted options for 1,500 shares of common stock at the same $6.81 exercise price. These 1,500-share options vest in 12 equal monthly installments on the 21st day of each month beginning June 21, 2026, and both grants were made under the Clene Inc. Amended 2020 Stock Plan.
Clene Inc. insider filings show that shares held indirectly for investor Ugwumba Chidozie through SymBiosis II, LLC were sold in two open-market transactions. The entity sold a total of 95,473 shares of common stock at prices of $6.20 and $6.75 per share, leaving 103,417 shares indirectly held after the most recent sale.
Clene Inc. insider activity: An entity associated with major shareholder Ugwumba Chidozie, identified as SymBiosis II, LLC, reported open-market sales of Clene Inc. common stock. On May 1, 2026, SymBiosis II, LLC sold 5,795 shares at $6.01 per share. On May 4, 2026, it sold an additional 72,884 shares at $6.80 per share. After the May 4 transaction, SymBiosis II, LLC continued to hold 198,890 shares of Clene Inc. common stock indirectly on behalf of Ugwumba Chidozie.
Clene Inc. ten percent owner associated entity SymBiosis II, LLC sold 19,497 shares of Common Stock in open-market transactions. The sales occurred over three days at prices of $5.63, $5.90, and $6.08 per share. After these indirect sales, 277,569 shares of Clene Common Stock remain held through SymBiosis II, LLC.
Clene Inc. insider associated entity sells shares in two open-market transactions. An entity linked to ten percent owner Ugwumba Chidozie, identified as SymBiosis II, LLC, sold 4,318 shares of Clene common stock at $6.12 per share on April 20, 2026, followed by 61,345 shares at $6.14 per share on April 21, 2026. After the April 21 sale, the filing reports 297,066 Clene shares indirectly held by this entity.
Clene Inc. ten percent owner Ugwumba Chidozie, through SymBiosis II, LLC, reported open-market sales of Clene common stock over three days. SymBiosis II, LLC sold 6,374 shares at $6.48 on April 15, 7,748 shares at $6.40 on April 16, and 25,040 shares at $6.43 on April 17, leaving 362,729 shares of indirect ownership after the latest transaction.
Clene Inc. insider filing shows an indirect share sale by a large holder. On April 2, 2026, SymBiosis II, LLC, an entity associated with ten percent owner Ugwumba Chidozie, completed an open-market sale of 24,925 shares of Clene common stock at $4.81 per share. Following this transaction, the entity continued to hold 401,891 shares of common stock indirectly, indicating the sale represented only a portion of its overall position.
Clene Inc. ten percent owner associated entity sells shares. An entity linked to Ugwumba Chidozie, SymBiosis II, LLC, completed an open-market sale of 4,278 shares of Clene Inc. common stock at $4.97 per share. After this transaction, the entity still holds 426,816 shares indirectly.
Clene Inc. ten-percent owner Ugwumba Chidozie, through Symbiosis II, LLC, reported open-market sales of Clene common stock. The LLC sold 67,991 shares at $4.88, 15,536 shares at $5.10, and 17,470 shares at $4.75 per share. Following these transactions, Symbiosis II, LLC continued to hold 431,094 shares of Clene common stock indirectly attributed to Chidozie.
Clene Inc. disclosed that an entity associated with ten percent owner Ugwumba Chidozie, identified as SymBiosis II, LLC, sold a total of 17,909 shares of Clene common stock in three open-market transactions at prices between $5.40 and $5.78 per share. After these indirect sales, SymBiosis II, LLC continued to hold 532,091 Clene shares.
Clene Inc. director Vallerie McLaughlin was awarded a stock option covering 3,030 shares of Common Stock. The option was granted on February 19, 2026 under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.73 per share.
The filing shows this as a derivative acquisition with no cash paid at grant. According to the disclosure, the option vests immediately upon grant and leaves McLaughlin with 3,030 derivative shares following the transaction, reflecting a new equity-based incentive rather than an open-market share purchase.
Clene Inc. director Reed N. Wilcox reported an equity award in the form of stock options. He was granted options covering 3,306 shares of common stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.73 per share.
The options vest immediately upon grant, giving him the right to purchase these shares at the stated exercise price. Following this grant, his directly held derivative securities position from this option award is reported as 3,306 options.
Clene Inc. director Alison Mosca received a grant of stock options as equity compensation. On February 19, 2026, she was awarded options for 4,201 shares of common stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.73 per share. The options vested immediately upon grant, giving her the right to purchase the underlying shares at this fixed price.
Clene Inc. director David J. Matlin received a stock option grant covering 5,372 shares of Common Stock. The option was granted on February 19, 2026 under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.73 per share and vests immediately upon grant.
Clene Inc. director Arjun JJ Desai reported an award of stock options. On February 19, 2026, he received an option grant for 3,168 shares of common stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.73 per share. The footnote states these options vest immediately upon grant, giving him the right to purchase Clene shares at that price going forward.
Clene Inc. director Jacobovitz Shalom reported receiving a stock option grant for 4,098 shares of common stock. The option was granted on February 19, 2026 under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.73 per share.
The option vests immediately upon grant, meaning it is fully exercisable right away. Following this award, Shalom holds stock options for 4,098 shares, all reported as directly owned. This is a compensation-related equity grant rather than an open-market share purchase.
Clene Inc. director Jonathon Gay reported receiving a grant of stock options. The award covers 3,271 shares of Common Stock, granted on February 19, 2026 under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.73 per share. The options vest immediately upon grant, and Gay now directly holds 3,271 stock options following this acquisition.
Clene Inc. director Matthew Kiernan received a grant of stock options covering 2,755 shares of common stock. The options were granted on February 19, 2026 under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.73 per share and vest immediately upon grant.
Clene Inc. insider activity: A Form 4 shows that on February 3, 2026, 5,559 shares of Clene Inc. common stock were sold at $4.10 per share. The shares are held indirectly through Symbiosis II, LLC, an entity associated with 10% owner Ugwumba Chidozie.
After this transaction, 550,000 Clene shares remain beneficially owned indirectly via Symbiosis II, LLC. The filing is for one reporting person and does not involve any derivative securities.
Clene Inc.’s 10% owner Chidozie Ugwumba, through affiliated entity Symbiosis II, LLC, reported a series of indirect open‑market sales of Clene common stock. The LLC sold 15,284 shares at $4.32 on January 29, 5,686 shares at $4.13 on January 30, and 3,800 shares at $4.04 on February 2, 2026. Following the latest transaction, 555,559 shares of Clene common stock are reported as indirectly owned by Symbiosis II, LLC.
Clene Inc.’s 10% owner Ugwumba Chidozie reported a series of indirect share sales through Symbiosis II, LLC. On January 26, 2026, Symbiosis II, LLC sold 6,418 shares of Clene common stock at $5.02 per share. On January 27, 2026, it sold 4,139 shares at $5.08 per share. On January 28, 2026, it sold 8,717 shares at $4.91 per share. Following the latest transaction, Symbiosis II, LLC beneficially owned 580,329 Clene common shares indirectly attributed to the reporting person.
Clene Inc. 10% owner Ugwumba Chidozie reported indirect sales of Clene common stock through Symbiosis II, LLC. On January 22, 2026, Symbiosis II, LLC sold 12,665 shares of common stock at $5.32 per share, after which it held 605,159 shares beneficially. On January 23, 2026, it sold a further 5,556 shares at $5.27 per share, leaving 599,603 shares beneficially owned indirectly by the reporting person.
Clene Inc.'s Chief Financial Officer received a new stock option grant. On January 22, 2026, CFO Morgan R. Brown was granted a stock option covering 35,000 shares of Clene Inc. common stock under the company’s Amended 2020 Stock Plan. The option has an exercise price of $5.42 per share and is reported as held directly. According to the disclosure, the options vest immediately upon grant, meaning they are fully exercisable from the grant date, and following this transaction the reporting person beneficially owns 35,000 derivative securities tied to common stock.
Clene Inc.'s Chief Science Officer, Mark Mortenson, received a new stock option grant. On January 22, 2026, he was awarded options to purchase 75,000 shares of Clene Inc. common stock at an exercise price of $5.42 per share under the Clene Inc. Amended 2020 Stock Plan. The filing notes that these options vest immediately upon grant, meaning they are fully exercisable right away. Following this grant, Mortenson holds 75,000 derivative securities (stock options) directly.
Clene Inc. reported an insider equity award for President and CEO Robert Dee Etherington, who is also a director. On January 22, 2026, he received a stock option for 75,000 shares of common stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $5.42 per share. The footnote explains that these options vest immediately upon grant and are exercisable until January 21, 2036. Following this grant, Etherington directly holds 75,000 derivative securities in the form of these stock options.
Clene Inc. 10% owner Ugwumba Chidozie, through Symbiosis II, LLC, reported three open-market sales of Clene common stock. On January 16, 2026, Symbiosis II, LLC sold 7,923 shares at $5.13 per share. On January 20, 2026, it sold a further 12,432 shares at $4.80 per share, and on January 21, 2026, it sold 12,119 shares at $5.05 per share. After the last transaction, Symbiosis II, LLC indirectly held 617,824 shares of Clene common stock, reflecting the updated ownership position associated with the reporting person.
Clene Inc. reported insider activity by a 10% owner. An entity identified as Symbiosis II, LLC, associated with reporting person Ugwumba Chidozie, sold Clene common stock over three days in January 2026. The sales were 26,105 shares on January 13, 2026 at $4.89 per share, 19,621 shares on January 14, 2026 at $5.12 per share, and 12,563 shares on January 15, 2026 at $5.10 per share. After these transactions, Symbiosis II, LLC was reported to indirectly hold 650,298 Clene common shares.
Clene Inc. director Alison Mosca reported indirect ownership changes tied to entities she is associated with, mainly Kensington Clene 2021, LLC. On January 9, 2026, Kensington Clene 2021, LLC made an in-kind distribution of 57,219 shares of common stock and matching Tranche A and Tranche B warrants for no consideration, leaving it with 263,833 common shares and 62,500 Tranche A and 62,500 Tranche B warrants held indirectly. On January 13, 2026, under a Securities Purchase Agreement effective that day, Kensington Clene 2021, LLC acquired 16,667 common shares at $6.00 per share plus 20,000 Series A warrants and 46,667 Series B warrants, all held indirectly. Additional common shares are reported as indirectly held through Kensington Investments, L.P. and the Robert C. Gay 1998 Family Trust, with Ms. Mosca disclaiming beneficial ownership where she has no pecuniary or profits interest.